Page 7 - சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Patients with breast cancer with distant lymph node metastases (DLNM) had similar survival to that of patients with regional node involvement and significantly better survival than those with non-DLNM distant spread, an analysis of 2,000 cases showed. Women with DLNM at diagnosis had a 3-year breast cancer-specific survival (BCSS) rate of 64.54% versus 63.24% for patients with ipsilateral supraclavicular lymph node metastases (ISLM) and 41.20% for those with distant metastases. Overall survival (OS) at 3 years was also similar between ISLM and DLNM, but significantly worse for patients with non-DLNM distant metastases. The results, derived from Surveillance, Epidemiology, and End Results (SEER) registry data, suggest that DLNM should be considered regional disease warranting aggressive treatment, reported Wenbin Zhou, MD, PhD, of Nanjing Medical University in China, and co-authors in

Wenbin zhouYutian zouCharles bankheadSun yat sen university cancer centerEnd resultsNanjing medical universityMedpage todayBreast cancerCarcinoma of breastMalignant tumor of breastசார்லஸ் வங்கித் தலைசூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம்முடிவு முடிவுகள்நான்ஜிங் மருத்துவ பல்கலைக்கழகம்மார்பக புற்றுநோய்புற்றுநோய் ஆஃப் மார்பக